Radiopharmaceuticals (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 5 | Progressive supranuclear palsy | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03926702 (ClinicalTrials.gov) | June 18, 2019 | 22/4/2019 | Tau Imaging With JNJ067 | Tau Imaging With JNJ067 | Alzheimer Disease;Mild Cognitive Impairment;Progressive Supranuclear Palsy | Drug: Radiopharmaceuticals | University of California, Berkeley | University of California, San Francisco | Active, not recruiting | 50 Years | N/A | All | 18 | Early Phase 1 | United States |
| 2 | NCT02167594 (ClinicalTrials.gov) | August 12, 2014 | 17/6/2014 | Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers | 18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers | Progressive Supranuclear Palsy;Corticobasal Degeneration | Drug: Flortaucipir F18;Procedure: Brain PET scan | Avid Radiopharmaceuticals | NULL | Completed | 50 Years | 85 Years | All | 29 | Phase 1 | United States |